Skip to main content
  1. Market Insights
  2. Health
  3. Pharmaceuticals

Anti-Coagulants - GCC

GCC
  • The Anti-Coagulants market in the GCC is expected to witness significant growth in the coming years.
  • According to projections, the revenue in this market is set to reach US$283.60m in 2024.
  • Furthermore, it is anticipated that the market will experience an annual growth rate of 7.54% from 2024 to 2029, resulting in a market volume of US$407.90m by the end of 2029.
  • When comparing the global market, it is noteworthy that United States is expected to generate the highest revenue in the Anti-Coagulants market.
  • In 2024 alone, the projected revenue for the United States is estimated to be a staggering US$16.74bn.
  • Despite the high prevalence of cardiovascular diseases in the GCC, the use of novel oral anticoagulants is still relatively low in the region.

Definition:
The Anti-Coagulants market covers drugs that prevent blood from clotting, i.e., that prolong the clotting time. Anti-coagulants are certain types of antithrombotics, which are often also called blood thinners. Neither thrombolytic drugs, which dissolve clots after they have formed, nor other anti-thrombotics, such as antiplatetelet drugs, are covered in this market.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Bristol Myers Squibb, Bayer, Sanofi, Johnson & Johnson

In-Scope

  • Blood clotting inhibitors

Out-Of-Scope

  • Anti-fibrinolytics
  • Anti-hypertensives
  • Other hematology drugs
  • Other anti-thrombotic agents, such as platelet aggregation inhibitors
  • Thrombolytic drugs
Anti-Coagulants: market data & analysis - Cover

Market Insights report

Anti-Coagulants: market data & analysis

Study Details

    Revenue

    Notes: Data shown is using current exchange rates and reflects market impacts of the Russia-Ukraine war.

    Most recent update: Jun 2024

    Source: Statista Market Insights

    Notes: The chart “Comparable Estimates” shows the forecasted development of the selected market from different sources. Please see the additional information for methodology and publication date.

    Most recent update: Mar 2024

    Analyst Opinion

    The Anti-Coagulants market in GCC has been steadily growing in recent years, driven by various factors such as an aging population and an increase in the prevalence of cardiovascular diseases.

    Customer preferences:
    Patients in the GCC region are increasingly opting for anticoagulant therapy as a preventative measure against stroke and other cardiovascular diseases. The preference for non-vitamin K antagonist oral anticoagulants (NOACs) has also been on the rise due to their ease of use and lower risk of bleeding compared to traditional anticoagulants.

    Trends in the market:
    Saudi Arabia has been the largest market for anticoagulants in the GCC, with a significant portion of the population being over the age of 65. This trend is expected to continue, with the aging population driving demand for anticoagulant therapy. Furthermore, the COVID-19 pandemic has increased the risk of thrombosis, leading to a surge in demand for anticoagulants.

    Local special circumstances:
    The GCC region has a high prevalence of obesity, diabetes, and hypertension, which are risk factors for cardiovascular diseases. This has contributed to the growing demand for anticoagulant therapy. Additionally, the region has a high incidence of consanguineous marriages, which can lead to an increased risk of genetic disorders such as thrombophilia, further driving demand for anticoagulant therapy.

    Underlying macroeconomic factors:
    The GCC countries have been investing heavily in their healthcare infrastructure, with a focus on improving access to healthcare services. This has led to increased awareness about the importance of preventive healthcare and early detection of diseases, including cardiovascular diseases. Additionally, the region has a high disposable income, which has enabled patients to afford the high cost of anticoagulant therapy. The GCC countries have also been diversifying their economies, which has led to an increase in foreign investment and a growing healthcare sector. This has created opportunities for pharmaceutical companies to expand their presence in the region and tap into the growing demand for anticoagulant therapy.

    Global Comparison

    Most recent update: Jun 2024

    Source: Statista Market Insights

    Methodology

    Data coverage:

    Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

    Modeling approach / Market size:

    Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

    Forecasts:

    In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

    Additional notes:

    Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

    Health

    Access more Market Insights on Health topics with our featured report

    Anti-Coagulants: market data & analysis - BackgroundAnti-Coagulants: market data & analysis - Cover

    Key Market Indicators

    Notes: Based on data from IMF, World Bank, UN and Eurostat

    Most recent update: Sep 2024

    Source: Statista Market Insights

    Explore more high-quality data on related topic

    Global pharmaceutical industry - statistics & facts

    The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.
    More data on the topic

    Contact

    Get in touch with us. We are happy to help.